Kraj: Australia
Język: angielski
Źródło: Department of Health (Therapeutic Goods Administration)
metformin hydrochloride, Quantity: 500 mg; ertugliflozin pyroglutamic acid, Quantity: 9.713 mg (Equivalent: ertugliflozin, Qty 7.5 mg)
Merck Sharp & Dohme (Australia) Pty Ltd
Tablet, film coated
Excipient Ingredients: crospovidone; sodium lauryl sulfate; microcrystalline cellulose; Carnauba Wax; povidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red
Oral
14, 56
(S4) Prescription Only Medicine
MSD-ERTUGLIFLOZIN-METFORMIN (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials and 4.2 DOSE AND METHOD OF ADMINISTRATION]
Visual Identification: Red, oval, film-coated tablets debossed with '7.5/500' on one side and plain on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius
Licence status A
2018-05-17